Phaseline

Targets › SLC1A2

SLC1A2 (Excitatory amino acid transporter 2): drug programs, companies and trials

3 programs from 3 companies in 8 trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Neurology, Immunology, Ophthalmology; next expected readout Dec 2026.

Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. (UniProt, P43004)

Open in Phaseline: the race on SLC1A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, Los AngelesCBD 20 mg
GABA-A receptor; anion channel positive allosteric modulator
HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3Phase 3Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury …Dec 2026
David Wilson[18F]RP-115
EAAT2 (SLC1A2) PET tracer
SLC1A2Phase 1Alzheimer DiseaseApr 2027
iQure AustraliaiQ-007
Positive allosteric modulator of excitatory amino acid transporter-2 (EAAT2)
SLC1A2Phase 1Drug Resistant Epilepsy–

Conditions

Spinocerebellar Ataxias (1) Non-healing Wound (1) Sleep Apnea, Obstructive (1) Cervical Spinal Cord Injury (1) Limbal Stem-cell Deficiency (1) Abuse, Drug (1) Drug Resistant Epilepsy (1) Alzheimer Disease (1)

Modalities

small molecule (3)

Companies

University of California, Los Angeles (1) iQure Australia (1) David Wilson (1)

Related targets

HTR1A (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) SLC1A3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.